HealthCare Royalty is acquiring royalties from Iqirvo, a novel treatment for primary biliary cholangitis, which enhances Genfit’s cash flow and supports its ongoing development efforts.

Information on the Target

Iqirvo® (elafibranor) is a groundbreaking, once-daily oral medication that acts as a dual agonist for peroxisome proliferator-activated receptors (PPAR) alpha and delta. It is specifically indicated for the treatment of primary biliary cholangitis (PBC) in adults who have not responded adequately to ursodeoxycholic acid (UDCA) or for those who cannot tolerate UDCA. PBC is a rare and chronic liver disease predominantly affecting women, characterized by the destruction of interlobular bile ducts. This condition leads to cholestasis, hindering the liver's ability to effectively clear toxins, which can ultimately progress to severe complications such as liver fibrosis, cirrhosis, and liver failure.

In June 2024, Iqirvo received accelerated approval from the U.S. Food and Drug Administration (FDA), followed by conditional marketing authorization from the European Me